CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 5,700 Shares

CeriBell (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 5,700 shares of the firm's stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the sale, the chief executive officer now directly owns 746,451 shares of the company's stock, valued at $11,211,694.02. The trade was a 0.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Monday, April 21st, Xingjuan Chao sold 3,372 shares of CeriBell stock. The stock was sold at an average price of $15.03, for a total transaction of $50,681.16.

CeriBell Price Performance

Shares of CBLL opened at $14.54 on Tuesday. The stock's 50 day moving average price is $20.16. CeriBell has a one year low of $10.01 and a one year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million. As a group, equities analysts predict that CeriBell will post -2.46 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of CeriBell in a report on Friday, April 4th. They set a "buy" rating and a $32.00 price objective on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 target price on shares of CeriBell in a research report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $32.50.

Hedge Funds Weigh In On CeriBell

Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc purchased a new stake in shares of CeriBell during the 4th quarter valued at approximately $32,000. Summit Investment Advisors Inc. acquired a new stake in CeriBell during the fourth quarter worth $33,000. Tower Research Capital LLC TRC purchased a new stake in CeriBell in the fourth quarter valued at $37,000. BNP Paribas Financial Markets acquired a new position in shares of CeriBell in the 4th quarter valued at $43,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of CeriBell during the 4th quarter worth about $47,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.